# Kate Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kate-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.katetherapeutics.com
- Total disclosed funding: $51M
- Latest round: Series A (Jun 8, 2023)
- Investors on record: 4

## About

Based in California, US, Kate Therapeutics, Inc. operates as a biotechnology research company that develops gene therapies using novel technology platforms. The company was co-founded by Eric Wang and Alan Beggs. As of 2023, the company is headed by its CEO Kevin Forrest. In June 2023, the firm raised USD 51 million in Series A funding co-led by investors Westlake Village BioPartners and Versant Ventures, with participation from investors OUP (Osage University Partners) and UF Innovate Ventures.

The company offers adeno-associated virus-based gene therapies to treat genetically defined muscle and heart diseases. The firm develops optimal capsid and cargo combinations that aim to treat cardiac as well as muscle disease.

The company plans to use the June 2023 funding to support the advancement of KateTx’s initial internal portfolio of muscle and heart disease programs.

## Funding rounds

- Series A, Jun 8, 2023, $51M — Versant Ventures, OUP (Osage University Partners), Westlake Village BioPartners, UF Innovate Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A
- UF Innovate Ventures (https://capitalatlas.ai/funds/uf-innovate-ventures) — Series A